These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 28060954)

  • 1. Activation of the mTOR Pathway by Oxaliplatin in the Treatment of Colorectal Cancer Liver Metastasis.
    Lu M; Zessin AS; Glover W; Hsu DS
    PLoS One; 2017; 12(1):e0169439. PubMed ID: 28060954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Translationally controlled tumour protein TCTP is induced early in human colorectal tumours and contributes to the resistance of HCT116 colon cancer cells to 5-FU and oxaliplatin.
    Bommer UA; Vine KL; Puri P; Engel M; Belfiore L; Fildes K; Batterham M; Lochhead A; Aghmesheh M
    Cell Commun Signal; 2017 Feb; 15(1):9. PubMed ID: 28143584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic inhibitory effects on hepatocellular carcinoma with recombinant human adenovirus Aspp2 and oxaliplatin via p53-independent pathway in vitro and in vivo.
    Liu X; Xu J; Wang S; Yu X; Kou B; Chai M; Zang Y; Chen D
    Int J Oncol; 2017 Oct; 51(4):1291-1299. PubMed ID: 28902369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-myc downstream-regulated gene 1 promotes oxaliplatin-triggered apoptosis in colorectal cancer cells via enhancing the ubiquitination of Bcl-2.
    Yang X; Zhu F; Yu C; Lu J; Zhang L; Lv Y; Sun J; Zheng M
    Oncotarget; 2017 Jul; 8(29):47709-47724. PubMed ID: 28537875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the NF-κB pathway by nafamostat mesilate suppresses colorectal cancer growth and metastasis.
    Lu YX; Ju HQ; Wang F; Chen LZ; Wu QN; Sheng H; Mo HY; Pan ZZ; Xie D; Kang TB; Chen G; Yun JP; Zeng ZL; Xu RH
    Cancer Lett; 2016 Sep; 380(1):87-97. PubMed ID: 27322737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
    Nukatsuka M; Nakagawa F; Takechi T
    Anticancer Res; 2015 Sep; 35(9):4605-15. PubMed ID: 26254349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
    Liu J; Zhang L; Zhang X; Xing X
    J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib, a Src inhibitor, sensitizes liver metastatic colorectal carcinoma to oxaliplatin in tumors with high levels of phospho-Src.
    Perez M; Lucena-Cacace A; Marín-Gómez LM; Padillo-Ruiz J; Robles-Frias MJ; Saez C; Garcia-Carbonero R; Carnero A
    Oncotarget; 2016 May; 7(22):33111-24. PubMed ID: 27105527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Luteolin sensitizes two oxaliplatin-resistant colorectal cancer cell lines to chemotherapeutic drugs via inhibition of the Nrf2 pathway.
    Chian S; Li YY; Wang XJ; Tang XW
    Asian Pac J Cancer Prev; 2014; 15(6):2911-6. PubMed ID: 24761924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ursolic acid synergistically enhances the therapeutic effects of oxaliplatin in colorectal cancer.
    Shan J; Xuan Y; Zhang Q; Zhu C; Liu Z; Zhang S
    Protein Cell; 2016 Aug; 7(8):571-85. PubMed ID: 27472952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer.
    Chen ZH; Qi JJ; Wu QN; Lu JH; Liu ZX; Wang Y; Hu PS; Li T; Lin JF; Wu XY; Miao L; Zeng ZL; Xie D; Ju HQ; Xu RH; Wang F
    J Exp Clin Cancer Res; 2019 May; 38(1):196. PubMed ID: 31088567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.
    Gaur S; Chen L; Ann V; Lin WC; Wang Y; Chang VH; Hsu NY; Shia HS; Yen Y
    Mol Cancer; 2014 Feb; 13():21. PubMed ID: 24495750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In Vivo Delivery and Therapeutic Effects of a MicroRNA on Colorectal Liver Metastases.
    Oshima G; Guo N; He C; Stack ME; Poon C; Uppal A; Wightman SC; Parekh A; Skowron KB; Posner MC; Lin W; Khodarev NN; Weichselbaum RR
    Mol Ther; 2017 Jul; 25(7):1588-1595. PubMed ID: 28457664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic antitumor effects of endostar in combination with oxaliplatin via inhibition of HIF and CXCR4 in the colorectal cell line SW1116.
    Jin F; Ji H; Jia C; Brockmeier U; Hermann DM; Metzen E; Zhu Y; Chi B
    PLoS One; 2012; 7(10):e47161. PubMed ID: 23071744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer.
    Zhang Y; Wang X; Qin X; Wang X; Liu F; White E; Zheng XF
    EBioMedicine; 2015 Dec; 2(12):1944-56. PubMed ID: 26844273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming Growth Factor β Mediates Drug Resistance by Regulating the Expression of Pyruvate Dehydrogenase Kinase 4 in Colorectal Cancer.
    Zhang Y; Zhang Y; Geng L; Yi H; Huo W; Talmon G; Kim YC; Wang SM; Wang J
    J Biol Chem; 2016 Aug; 291(33):17405-16. PubMed ID: 27330076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NFYB-induced high expression of E2F1 contributes to oxaliplatin resistance in colorectal cancer via the enhancement of CHK1 signaling.
    Fang Z; Gong C; Yu S; Zhou W; Hassan W; Li H; Wang X; Hu Y; Gu K; Chen X; Hong B; Bao Y; Chen X; Zhang X; Liu H
    Cancer Lett; 2018 Feb; 415():58-72. PubMed ID: 29203250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.
    Ning Y; Labonte MJ; Zhang W; Bohanes PO; Gerger A; Yang D; Benhaim L; Paez D; Rosenberg DO; Nagulapalli Venkata KC; Louie SG; Petasis NA; Ladner RD; Lenz HJ
    Mol Cancer Ther; 2012 Jun; 11(6):1353-64. PubMed ID: 22391039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.